The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, OptumRx and Express Scripts.
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" prescription price hikes of 1,000% or more.
The accused killer of Brian Thompson cited the industry’s failures as his motive for assassinating the UnitedHealth executive on the streets of New York. Luigi Mangione ended up receiving an outpouring of support on social media from Americans furious how the Minnesota-based company mistreated their loved ones.
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark, Express Scripts and Optum Rx) on specialty generic drugs,
FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging, PBMs, UnitedHealth OptumRx, CVS Caremark Rx, Express Scripts
CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging margins.
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through
The three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty generic drugs for cancer, HIV and other conditions, the Federal Trade Commission charged on Tuesday.
UnitedHealth, in which slain CEO Brian Thompson was employed, has been allegedly accused of overcharging patients suffering from dangerous and severe cancer by near about more than 1000% for their medication.
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive.
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal Trade Commission (FTC) uncovered in its second interim staff report rele | The FTC released its second interim staff report Tuesday during Chair Lina Khan's final open commission meeting,
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from price gouging.